We develop and optimize liposomes, polymeric micelles, or inorganic nanoparticles, etc., to utilize the passive Enhanced Permeability and Retention (EPR) effect; or we modify the carriers with tumor-specific ligands (such as folic acid, RGD peptides) to achieve active and efficient enrichment of sonosensitive agents in tumors.
Targeting Delivery for Sonodynamic Therapy
Sonodynamic therapy (SDT) is a non-invasive, targeted technique that uses low-intensity ultrasound to activate a sonodynamic agent, generating reactive oxygen species (ROS) to kill tumor cells. While SDT offers deep penetration, its efficacy depends entirely on the precise accumulation of the agent at the tumor site. Creative Biolabs provides targeted delivery technology development, focusing on nanocarrier engineering to address the core challenges of sonodynamic agent accumulation in vivo, microenvironment response, and activation efficiency.
Click Here to View more about our Service
What is Targeted Delivery?
In the field of SDT, "targeted delivery" is the technological guarantee for achieving targeted therapeutic effects. It refers to:
Tumor Enrichment: Encapsulating sonodynamic agents in nanocarriers and utilizing enhanced penetration and retention (EPR) or active targeting to increase the concentration of sonodynamic agents in tumor tissue.
Microenvironment Responsiveness: Designing carriers to precisely release sonodynamic agents or enhance their activity in response to stimulation by the tumor microenvironment (e.g., low pH, high reduction potential, specific enzymes).
Synergistic Effect: The carrier can simultaneously deliver SDT enhancers or chemotherapeutic drugs, achieving a synergistic effect between sonodynamics and chemotherapy.
Applications for Sonodynamic Therapy
The technical support offered by specialized delivery platforms enables key innovations in SDT:
Non-invasive Treatment of Deep Tumors
The technology delivers highly effective sonodynamic agents (such as porphyrins or nanomaterials) for non-invasive, localized, targeted removal of deep solid tumors (e.g., liver cancer, pancreatic cancer), overcoming the depth limitations of light-based therapies.
Enhanced SDT Efficacy
Encapsulating hypoxia-sensitive sonosensitive agents or ROS enhancers in a carrier overcomes the hypoxia problem prevalent in the tumor microenvironment, maximizing the local reactive oxygen species production activity under ultrasound.
Combination Therapy Strategies
Developing multifunctional nanocarriers is crucial to simultaneously deliver sonosensitive agents and complementary therapeutic drugs, achieving powerful synergistic sonodynamic-chemotherapy or sonodynamic-immunotherapy outcomes.
Fig.1 Schematic of micelle-based combination chemo-sonodynamic cancer therapy.1
Delivery Challenges of Sonodynamic Therapy
- Insufficient Tumor-Targeted Enrichment: Traditional sonosensitive agents lack specificity in vivo distribution, leading to systemic toxicity and insufficient concentration at the tumor site, which severely compromises therapeutic efficacy.
- Lack of Microenvironment Responsiveness: The activity of many sonosensitive agents may be inhibited by the harsh characteristics of the tumor microenvironment (e.g., hypoxia). A responsive carrier is needed to protect the sonosensitive agent or achieve environment-triggered release.
- In vivo Stability and Cycle Time: Many sonosensitive agents have poor water solubility and are prone to aggregation and inactivation in vivo, requiring highly efficient nanoencapsulation strategies to prolong their cycle time and maintain crucial stability.
What We Can Offer
We offer professional targeted delivery technologies, focusing on solving the challenges of sonosensitive agent (SDA) enrichment, responsiveness, and activity:
Active/Passive Tumor Targeting Carriers
Tumor Microenvironment Responsive Release
We design low-pH, reduction-sensitive, or enzyme-responsive nanocarriers to ensure precise and rapid release of sonosensitive agents or triggering of their activity only upon arrival at the specific tumor microenvironment cue.
Multifunctional Synergistic Delivery Systems
We specialize in integrating sonosensitive agents with hypoxia-relieving agents/chemotherapeutic drugs into a single nanoplatform to achieve robust synergistic effects of SDT with other treatment modalities (e.g., Chemo-SDT, Sono-Immunotherapy).
SDT Activation Optimization
We rigorously evaluate the encapsulation efficiency of different carriers for sonosensitive agents and analyze the Reactive Oxygen Species (ROS) generation activity under standardized ultrasound activation to ensure the highest possible therapeutic efficiency.
Why Choose Us?
Unmatched Expertise
Leverage decades of experience in nanomedicine and developing stimuli-responsive delivery systems.
Precision Activation
Deep specialization in Tumor Microenvironment (TME)-responsive carriers (pH, Redox, Enzyme) for highly precise SDT activation.
Pioneering Platforms
Leaders in advanced sonosensitizer platforms, including high-efficiency Metal-Organic Frameworks (MOFs) and targeted organelle systems (TPP).
Translation Focus
Dedicated commitment to clinical readiness, prioritizing robust scalability, safety, and regulatory compliance.
Workflow
The future of non-invasive, deep-tissue cancer treatment starts with precise delivery. Contact us today to discuss how we can accelerate your Sonodynamic Therapy program.
Reference
- Kang, Hyeon Ju, et al. "Efficient combination chemo-sonodynamic cancer therapy using mitochondria-targeting sonosensitizer-loaded polysorbate-based micelles." International Journal of Molecular Sciences 25.6 (2024): 3474. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijms25063474
Our services are For Research Use Only. We do not provide services to individuals.
Online Inquiry
